Tau PET Imaging in Neurodegenerative Disorders
Open accessAbstract
Decontamination of N95 respirators has become critical to alleviate PPE shortages for healthcare workers in the current COVID-19 emergency. The factors that are considered for the effective reuse of these masks are the fit, filter efficiency and decontamination/disinfection level both for SARS-CoV-2, which is the causative virus for COVID-19, and for other organisms of concern in the hospital environment such as Staphylococcus aureus or Clostridium difficile. In its guidance entitled ‘Recommendations for Sponsors Requesting EUAs for Decontamination and Bioburden Reduction Systems for Surgical Masks and Respirators During the Coronavirus Disease 2019 (COVID19) Public Health Emergency’ (May 2020)[1], the FDA recommends a 6-log10 reduction in either the most resistant bacterial spores for the system or in a mycobacterium species to authorize the use of a decontamination method of N95 respirators for single or multiple users. While the goal is primarily inactivation against SARS-CoV-2, testing of decontamination methods against the virus may not always be available. For decontamination methods considered for only single users, the recommendation is a 6-log10 reduction in the infective virus concentration of 3 non-enveloped viruses or in the concentration of two Gram (+) and two Gram (-) bacteria. Based on these recommendations, we explored the efficacy of vaporized H2O2 (VHP) treatment of N95 respirators against surrogate viruses covering a wide range of disinfection resistance for emergency decontamination and reuse to alleviate PPE shortages for healthcare workers in the COVID-19 emergency.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tau PET is approved by the FDA for in vivo assessment of tau in people with AD.
“Tau PET uses ligands that bind to neurofibrillary tangles. Tau PET is approved by the FDA for the in vivo assessment of tau in people with AD [178].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [178]
Tau PET uses ligands that bind to neurofibrillary tangles.
“Tau PET uses ligands that bind to neurofibrillary tangles. Tau PET is approved by the FDA for the in vivo assessment of tau in people with AD [178].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [178]
Several tau PET tracers have been developed, including first-generation (18F-AV1451/flortaucipir, 18F-THK family, 11C-PBB3) and newer tracers (18F-MK6240, 18F-R0948, 18F-PI260, 18F-GTP1, 18F-JNJ-64326067).
“There are several tau PET tracers that have been developed so far with the initial first generation (18F-AV1451/now licensed for clinical use in US as flortaucipir, 18F-THK family and 11C-PBB3) and the newer tracers 18F-MK6240, 18F-R0948, 18F-PI260, 18F-GTP1, and 18F-JNJ-64326067 [178, 179].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [178]
The citation lists haven’t been fetched yet
References 78 · Cited by 137
- Authors
- Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R.
- Affiliations
- Lund University (SE)
- Montreal Neurological Institute and Hospital (CA)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2022-06
- Volume
- 63
- Issue
- Supplement 1
- Pages
- 20S-26S
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W4282016234
- Cited by
- 137
- References
- 78
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 33 · 2023: 15 · 2022: 4
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Pfizer
- Biogen
- Eisai
- Genentech
- Avid Radiopharmaceuticals
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- tau PET imaging, neurodegenerative diseases, tau protein, positron emission tomography, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cross-Sectional Studies, Humans, United States, tau Proteins, Neurodegenerative Diseases, Tauopathies, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review